Colombo 2012.

Methods	Phase III open‐label RCT conducted in 22 countries; accrual between Nov 2005 and Mar 2009 ID: NCT00262990
Participants	829 women with PR ROC following ≤ 3 platinum‐taxane based regimens. Measurable and non‐measurable disease (but CA125 elevated at baseline); ovarian, fallopian and primary peritoneal cancer included. Excluded if peripheral neuropathy, unresolved bowel obstruction or diarrhoea had within 7 days of start of treatment.
Interventions	Arm 1: PAT (10 mg/m²) IVI q3wk Arm 2: PLD (50 mg/m²) IVI q4wk No routine premedication was given to either arm.
Outcomes	Primary: OS Secondary: PFS, ORR, SAE
Notes	Women were assessed 8‐weekly; median follow‐up was 27 months. Arms received a median of 4.5 and 3 cycles for PAT and PLD respectively. Median TTP was 15.9 weeks for both arms. Median time to death was 56.6 weeks versus 54.4 weeks in favour of PAT.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Central randomisation.
Allocation concealment (selection bias)	Low risk	Allocation via an interactive voice response system.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Open‐label.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinded central review of results.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Very few women lost to follow‐up and low attrition (< 20%) in most analyses. As with other studies, QoL data suffered from high attrition rates and therefore we could not use it in the meta‐analyses.
Selective reporting (reporting bias)	Low risk	All expected outcomes were reported.
Other bias	Low risk	Baseline characteristics were similar.